Deleobuvir (formerly BI 207127) was an experimental drug for the treatment of hepatitis C. It was being developed by Boehringer Ingelheim.

[citation needed] Data from the SOUND-C2 study, presented at the 2012 AASLD Liver Meeting, showed that a triple combination of deleobuvir, faldaprevir, and ribavirin performed well in HCV genotype 1b patients.

[1] Efficacy fell below 50%, however, for dual regimens without ribavirin and for genotype 1a patients.

[citation needed] These results were confirmed in the SOUND-C3 study, presented at the 2013 APASL Liver Conference, which found that 16-week triple therapy with deleobuvir + faldaprevir + ribavirin gave 95% SVR12 in HCV genotype 1b patients but poor virological response in genotype 1a.

[2] In December 2013, Boehringer Ingelheim announced that the development of deleobuvir would not be continued since recent findings from phase III trials did not suggest sufficient efficacy.